Creso clinches commercialisation deal for cannaQIX® UK launch
Creso Pharma (ASX:CPH) has revealed it has penned a commercialisation agreement with Precision Healthcare to launch cannaQIX®10 and 50 in the UK. The launch is planned for the first quarter of the year.
Precision Healthcare is a UK-based privately held healthcare company which specialises in developing consumer healthcare products. It is part of Precision Marketing Group, a leading service provider to international pharmaceutical and healthcare companies. The company sells and distributes consumer healthcare brands to mass retailers and independent pharmacies covering more than 5000 points of sale in the UK.
CannaQIX® is CPH’s unique, proprietary formulated, nutraceutical product range containing full plant organic hemp extract with cannabidiol (CBD), vitamins and zinc. It aims to reduce stress and to support mental and nervous functions in humans.
The agreement covers the non-exclusive marketing and distribution of cannaQIX®10 and 50 in the UK market, targeting pharmacies and health food stores. This deal follows on from CPH’s receipt of confirmation for cannaQIX® as a food supplement from the UK Trading Standard Office (TSO).
Swiss regulatory authorities have issued a certificate of free sales for the export of the product into the UK from Switzerland.
While CPH has announced several positive developments, it should be noted here that it is in its early stages and investors should seek professional financial advice if considering this stock for their portfolio.
CPH CEO and co-founder, Dr Miri Halperin Wernli said: “We are delighted to partner with Precision Healthcare and to have obtained the necessary regulatory approvals for cannaQIX® in the UK – both significant milestones for our company.”
Precision Marketing Group CEO, Matthew Caldwell-Nichols added: “We are very pleased to work with Creso Pharma, who are a leading Swiss-based cannabis and hemp healthcare company, to market their innovative cannabis and hemp-based products, and we are looking forward to a successful business partnership.”
The cannaQIX® range
The cannaQIX® products are hemp-based nutraceuticals which utilise CPH’s proprietary innovative delivery technology.
The proprietary QIX-technology based delivery system contains capsicum, which accelerates blood circulation in the mouth, enhancing the buccal, sublingual delivery of the CBD, vitamins and zinc into the bloodstream.
The product is safe, well tolerated, non-euphoric, non-addictive and sugar-free. The standardised, user-friendly strength and formulation allows precise dosage control, ensuring a reliable and stable effect over several days.
The cannaQIX® range has been developed to Good Manufacturing Practice (GMP) standards and is produced in Switzerland by CPH’s partner, Swiss-based food and pharma development company, DOMACO Dr. med Aufdermaur AG (Domaco), to the highest Swiss quality and with a “Swiss Made” label.
With this product range, CPH is offering consumers a safe and effective certified food supplement with CBD, with broad market reach and without the need for medical prescriptions.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.